Top

Published in:

01-04-2011 | Original Article

Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?

Authors: Matthias Haas, Maike Büttner, Tilman T. Rau, Rainer Fietkau, Gerhard G. Grabenbauer, Luitpold V. Distel

Published in: Virchows Archiv | Issue 4/2011

Abstract

Tumor-infiltrating lymphocytes (TILs) in gastric adenocarcinoma show a strong compartmentalization with high numbers of lymphocytes in the stroma and low intraepithelial lymphocyte counts. Our previous study has shown stromal regulatory T cells (Treg) to be associated with a beneficial outcome in intestinal type cancer of the cardia. We undertook the present study to further evaluate the immunogenic and inflammatory environment in intestinal-type gastric adenocarcinoma of the cardia. We assessed CXCR3 expression, Epstein–Barr virus (EBV) status, Her2/ERBB2 status and overexpression/amplification using tissue microarrays (immunohistochemistry and in situ hybridization) of 52 patients. The data were correlated to different TIL subset counts (CD3, CD8, GranzymeB, FoxP3 and CD20) and to infiltrating histiocytes (CD68) both in the tumor and the surrounding stromal tissue that were reported earlier. Her2/ERBB2 overexpression/amplification showed no correlation to tumor stage. Moreover, for the first time, we show here that Her2/ERBB2 overexpression/amplification has no correlation to overall or subset-specific TIL infiltration. EBV infection was seen in four cases and showed a strong association with intratumoral CD8⁺ T cell infiltration as well as a moderate correlation to stromal CD8⁺ T cell accumulation. Intratumoral CD8⁺ T cell infiltration was significantly correlated to intratumoral FoxP3⁺ Treg infiltration, and to a lesser extent, to stromal FoxP3⁺ Treg counts. Stromal CXCR3⁺ T cell infiltration showed an inverse correlation to T category. This highlights the importance of stromal immune processes for cancer growth and suggests a subversion of Th1 immunoresponse in cancer progression and underlines the important role of inflammation for early carcinogenesis

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148. doi:10.1016/j.immuni.2004.07.017 PubMedCrossRef

Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ, Kuppen PJ (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84(4):493–501. doi:10.1038/labinvest.37000553700055 PubMedCrossRef

Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61(10):3932–3936PubMed

Solcia E, Klersy C, Mastracci L, Alberizzi P, Candusso ME, Diegoli M, Tava F, Riboni R, Manca R, Luinetti O (2009) A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch 455(3):197–211. doi:10.1007/s00428-009-0813-z PubMedCrossRef

Oudejans JJ, Harijadi H, Kummer JA, Tan IB, Bloemena E, Middeldorp JM, Bladergroen B, Dukers DF, Vos W, Meijer CJ (2002) High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 198(4):468–475. doi:10.1002/path.1236 PubMedCrossRef

Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJ (1997) Activated cytotoxic T cells as prognostic marker in Hodgkin’s disease. Blood 89(4):1376–1382PubMed

Piccirillo CA, Thornton AM (2004) Cornerstone of peripheral tolerance: naturally occurring CD4 + CD25+ regulatory T cells. Trends Immunol 25(7):374–380. doi:10.1016/j.it.2004.04.009 PubMedCrossRef

Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32. doi:1820102 PubMedCrossRef

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061. doi:10.1126/science.1079490 PubMedCrossRef

10.

Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 9:65. doi:1471-230X-9-65 PubMedCrossRef

11.

Ohno S, Tachibana M, Fujii T, Ueda S, Kubota H, Nagasue N (2002) Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int J Cancer 97(6):770–774. doi:10.1002/ijc.10144 PubMedCrossRef

12.

Krieg C, Boyman O (2009) The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol 19(2):76–83. doi:10.1016/j.semcancer.2008.10.011 PubMedCrossRef

13.

Syrbe U, Siveke J, Hamann A (1999) Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 21(3):263–285PubMedCrossRef

14.

Ohtani H, Yoshie O (2010) Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers. Virchows Arch 456(6):615–623. doi:10.1007/s00428-010-0921-9 PubMedCrossRef

15.

Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O (2009) Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 217(1):21–31. doi:10.1002/path.2448 PubMedCrossRef

16.

Watanabe H, Enjoji M, Imai T (1976) Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 38(1):232–243PubMedCrossRef

17.

Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, Ueda H, Ogino T, Nakanishi I (1990) Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor. Cancer 66(5):945–952PubMedCrossRef

18.

Takada K (2000) Epstein–Barr virus and gastric carcinoma. Mol Pathol 53(5):255–261PubMedCrossRef

19.

van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, Bloemena E (2004) EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22(4):664–670. doi:10.1200/JCO.2004.08.061 PubMedCrossRef

20.

Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS (2009) Clinicopathological and molecular characteristics of Epstein–Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 24(3):354–365. doi:10.1111/j.1440-1746.2009.05775.x PubMedCrossRef

21.

Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Ki Kang W, Kim M, Kim S, Park CK (2010) Host inflammatory response predicts survival of patients with Epstein–Barr virus-associated gastric carcinoma. Gastroenterology 139(1):84–92.e82. doi:10.1053/j.gastro.2010.04.002 PubMedCrossRef

22.

Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529. doi:10.1093/annonc/mdn169 PubMedCrossRef

23.

Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273–278. doi:10.1093/annonc/mdi064 PubMedCrossRef

24.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X PubMedCrossRef

25.

Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457(3):299–307. doi:10.1007/s00428-010-0952-2 PubMedCrossRef

26.

Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78(2):202–208. doi:10.1002/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.0.CO;2-C PubMedCrossRef

27.

Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B (2002) Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85:101–144PubMedCrossRef

28.

Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9(1):35–41. doi:S0960-7404(00)00021-9 PubMedCrossRef

29.

Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42(1):1–8PubMedCrossRef

30.

Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, Jellum E, McColl KE (2007) Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 56(7):918–925. doi:10.1136/gut.2006.114504 PubMedCrossRef

31.

Siman JH, Engstrand L, Berglund G, Forsgren A, Floren CH (2007) Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol 42(8):933–940. doi:10.1080/00365520601173863 PubMedCrossRef

32.

Tajima Y, Nakanishi Y, Yoshino T, Kokawa A, Kusano M, Shimoda T (2001) Clinicopathological study of early adenocarcinoma of the gastric cardia: comparison with early adenocarcinoma of the distal stomach and esophagus. Oncology 61(1):1–9. doi:ocl61001 PubMedCrossRef

33.

Powell J, McConkey CC (1990) Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 62(3):440–443PubMedCrossRef

34.

Sarbia M, Becker KF, Hofler H (2004) Pathology of upper gastrointestinal malignancies. Semin Oncol 31(4):465–475. doi:S0093775404002416 PubMedCrossRef

35.

Kalish RJ, Clancy PE, Orringer MB, Appelman HD (1984) Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and in the gastric cardia. Gastroenterology 86(3):461–467. doi:S0016508584000615 PubMed

36.

Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H (2008) Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98(1):148–153. doi:10.1038/sj.bjc.6604149 PubMedCrossRef

37.

Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6(3):205–217. doi:10.1038/nri1786 PubMedCrossRef

38.

Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54(14):3845–3852PubMed

39.

Krenauer A, Moll A, Ponisch W, Schmitz N, Niedobitek G, Niederwieser D, Aigner T (2010) EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression—a case report. Diagn Pathol 5:21. doi:10.1186/1746-1596-5-21 PubMedCrossRef

40.

Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T (1996) Transcriptional analysis of Epstein–Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 74(4):625–631PubMedCrossRef

Title: Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?
Authors: Matthias Haas
Maike Büttner
Tilman T. Rau
Rainer Fietkau
Gerhard G. Grabenbauer
Luitpold V. Distel
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 4/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1058-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Analysis of select members of the E26 (ETS) transcription factors family in colorectal cancer

Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type

Gene expression profiling of human hepatoblastoma using archived formalin-fixed and paraffin-embedded tissues

PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis

Kidney histologic alterations in α-Galactosidase-deficient mice

Diffuse lymphangiomatous hyperplasia of the spleen with hyaline bodies. A pseudotumoral proliferation arising from the lymphatic vessels of the periarteriolar lymphatic sheath